Compare Realty Income Corp (O) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Recursion Pharmaceuticals Inc — how do they compare? Realty Income Corp trades at $54.2 (market cap $51.26B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Realty Income Corp is far larger — about 24× Recursion Pharmaceuticals Inc's market cap, and Realty Income Corp pays a 6.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| O | RXRX | |
|---|---|---|
Market Cap | $51.26B | $2.14B |
Volume | 12,300,266 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $6.79 |
52-Week Low | $53.35 | $2.84 |
Typical Hold Time | 127 Days | 23 Days |
Enterprise Value | $81.88B | $1.66B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $54.09, down 1.39% amid a bearish technical signal and recent earnings misses. The stock faces pressure from rising Treasury yields, yet maintains a high gross margin of 92.56% and consistent dividend payments. Revenue growth is steady, with 2025 revenue at $5.75B, though net income margin has fluctuated. Analyst consensus is a Buy with a $64.80 price target, but technical indicators show resistance near $55.
The outlook for O hinges on its ability to navigate interest rate sensitivity while leveraging its robust property portfolio. Opportunities include a high dividend yield and strong operational cash flow, but risks involve debt levels nearing 40% of assets and competitive pressures in the REIT sector. Investor sentiment is cautious due to recent underperformance relative to the S&P 500.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
